Last updated: July 30, 2026
Executive summary: ISOVUE-370 (iohexol 370 mg iodine/mL) remains a niche, image-utilization-linked contrast agent sold primarily in the U.S. under a legacy brand footprint. Near-term financial trajectory is driven by two forces: (1) volume elasticity from diagnostic imaging mix (CT utilization) and seasonal hospital throughput, and (2) pricing pressure from private-label and generic iohexol products plus channel contracting. Commercial upside is largely constrained by the age of the brand, the breadth of generic substitution, and the limited scope for defensible incremental differentiation beyond labeling and supply continuity.
What is ISOVUE-370 (iohexol 370 mg I/mL) and how does it compete in X-ray contrast markets?
ISOVUE-370 is a non-ionic, iodinated X-ray contrast agent containing iohexol, dosed for intravascular and imaging indications. Commercially, it competes in the iodinated contrast space against other iohexol brands and non-iohexol alternatives (low-osmolar and iso-osmolar agents) that hospitals qualify through group purchasing organizations (GPOs) and multiyear supply contracts.
Key market structure factors for iodinated contrast agents
- Hospital formulary and GPO contracting dominates buying decisions more than prescriber preference.
- High switching risk for brands once generic or equivalent alternatives are available through contracted pricing.
- Tender cycles (quarterly/annual) can create lumpiness in sales even when underlying imaging demand is steady.
- Supply reliability matters because radiology departments schedule imaging capacity tightly.
Where ISOVUE-370 sits vs competitive chemistries
- Iohexol (ISOVUE-370) sits in a common “non-ionic, low-osmolar” category that is heavily represented by generics and private label.
- Against iso-osmolar agents (e.g., iodixanol), hospitals balance viscosity, patient tolerance, and clinical protocols, but commercial decisions still skew to contracted price and availability.
How have U.S. pricing and reimbursement pressures shaped ISOVUE-370 revenue?
Financial trajectory for an older iodinated contrast brand tracks reimbursement and procurement dynamics more closely than patent-driven pricing power. In practice, price pressure shows up as:
- Contracted unit price compression after generic entries and re-tendering.
- Channel mix shift between direct hospital buys, distributor inventory, and group purchasing channels.
- Competitive substitution at pharmacy and radiology procurement levels when equivalent concentrations and container sizes are contracted.
Pricing mechanics in hospital contrast procurement
- Radiology departments procure under:
- GPO master agreements
- IDNs (integrated delivery networks) with centralized purchasing
- Local contracts for radiology-owned inventory
- Generic and private-label iohexol products can reduce brand share quickly when:
- contracted equivalents are available at lower net price
- manufacturer rebates/incentives narrow the gap or do not fully offset competitor discounts
What typically happens to net sales in this category
- Brand revenue declines over time as contracted equivalents expand.
- Volatility increases around contract renewal windows.
- Gross-to-net erosion rises as the brand uses rebates and chargebacks to defend share.
When do generic iohexol products typically erode ISOVUE-370 share, and how does exclusivity timing impact revenue?
ISOVUE-370 is a legacy contrast product, and its commercial life is shaped by the fact that iodinated contrast markets experience early and repeat generic substitution cycles. Revenue decline typically accelerates after each procurement step function when:
- generic equivalents become broadly available in contracted channels
- radiology protocols formally accept alternative products
- container size or concentration variants shift toward cheaper supply
Revenue exposure mapping to substitution scenarios
- Best-case: brand maintains a meaningful slice of non-contracted buys through clinical preference, institutional continuity, or packaging convenience.
- Base-case: brand keeps residual share in accounts that delay re-tendering or have supply constraints with alternatives.
- Worst-case: loss of key GPO contracts triggers share drop and net price resets lower.
How big is the revenue opportunity and what is the likely financial trajectory for ISOVUE-370?
ISOVUE-370 is not positioned as a high-growth specialty asset. The financial trajectory is best characterized as:
- mature base sales supported by continued CT and imaging demand
- structural headwinds from generic substitution
- limited upside unless market share gains occur through contracting wins, new container/packaging formats, or supply stabilization
What drives annual directionality
- Imaging utilization: CT volume trends correlate with demand.
- Procurement cycles: quarter-to-quarter revenue swings correlate with tenders and inventory builds.
- Mix: changes in concentration, volume per procedure, and container format affect units and net pricing.
Scenario-based trajectory (directional)
| Scenario |
Share trend |
Net price trend |
Revenue trend over 12–24 months |
| Contract defense |
Flat to modest decline |
Stable to modest down |
Flatter sales curve |
| Retender loss |
Material share loss |
Downward |
Declining revenue with lumpiness |
| Supply-led substitution |
Mix shifts to alternatives |
Price declines |
Faster erosion even if demand is steady |
What patents and Orange Book listings affect ISOVUE-370 market exclusivity?
ISOVUE-370 is an established drug product, and U.S. exclusivity and patent barriers are typically minimal compared with newer chemical entities. For iodinated contrast agents, most competitive constraints come from:
- regulatory and labeling equivalence
- contracting and manufacturing capacity
- practical switching constraints, not ongoing patent thickets
What to expect in Orange Book dynamics for legacy injectables
- Multiple listed patents are common for drug products, but:
- patent enforcement leverage often wanes over time
- generic equivalence and FDA approval pathways limit long-run brand control
(For a precise, litigation-grade list of ISOVUE-370 Orange Book patents and expiries, brand-specific Orange Book entries and patent families must be mapped to the exact NDA and dosage forms. This requires product-level docketing data not included here.)
What patent litigation and Paragraph IV challenges have shaped competition for iohexol contrast brands?
For mature contrast products, the competitive catalyst is usually not active blockbuster-scale patent warfare but the cumulative effect of:
- generic approvals
- launch timing relative to patent expirations
- settlements that shift launch dates and sometimes preserve a remnant share
Typical settlement and launch pattern in legacy generics
- Brand sues around generic filing timing
- Settlement can result in a stipulated launch date
- Net market impact depends on whether the generic product is adopted in contracted channels quickly
(As with Orange Book mapping, full litigation coverage requires case-level sourcing tied to the exact ISOVUE-370 NDA and generic defendants.)
How does ISOVUE-370 compare with other iodinated contrast agents on market and procurement behavior?
Competitive set by practical substitution
- Other iohexol brands and equivalents
- Low-osmolar iodinated agents
- Iso-osmolar agents (clinical choice may differ; procurement may still go to contracted price)
Procurement behavior patterns that matter financially
- Hospitals often run multiple suppliers to manage supply shocks.
- Formularies may allow alternatives, but switching to cheaper suppliers occurs mostly during contract renewals or protocol updates.
- Clinical differentiation can protect usage in specific workflows, but for many accounts price is the primary lever.
Which companies dominate supply and contracting for iohexol contrast, and what does that mean for ISOVUE-370?
In this class, large generic manufacturers and contrast-focused suppliers typically gain leverage through:
- broad distribution
- manufacturing scale and redundancy
- ability to offer deeper rebates to GPOs and IDNs
For ISOVUE-370, that translates into:
- higher risk of share erosion after tender wins by lower-net-price competitors
- need to maintain supply reliability to prevent radiology departments from permanently switching
How do manufacturing and supply constraints affect ISOVUE-370 sales and profit margins?
Contrast injectables face margin swings from:
- raw material and packaging costs (iodine-chemistry upstream sensitivity)
- contract manufacturing and batch-release constraints
- logistics and distributor inventory cycles
Margin pressure channels
- Gross-to-net: increases when the brand uses pricing incentives to defend share.
- Obsolescence and expired inventory: if distributors hold excess inventory between contract cycles.
- Penalty costs: shortages can create backorder dynamics that shift purchases away from the brand.
How do regulatory and labeling changes impact ISOVUE-370 commercial performance?
Changes that can materially shift usage include:
- expanded or narrowed indications
- updated warnings/precautions
- modifications in dosing recommendations that affect clinical workflow
However, in legacy contrast categories, major label changes are less common than in new therapeutic classes; commercial trajectory typically remains procurement- and volume-driven.
What are the realistic generic entry risks for ISOVUE-370 in the next 24 months?
Generic entry risk in legacy iohexol products is usually “evergreen” because:
- multiple manufacturers can be approved
- concentration and container format can still offer entry opportunities
- channel availability and contract renewals can accelerate substitution
Financial implication: even if no new approvals occur, the brand can lose incremental share when contracted suppliers swap in cheaper products.
(Exact next-24-month entry triggers for ISOVUE-370 require NDA-level regulatory status tracking, including ANDA approval history and paragraph IV events, which is not provided here.)
How does ISOVUE-370 revenue exposure compare to broader iodinated contrast market cycles?
Iodinated contrast volumes tend to correlate with:
- outpatient imaging trends
- inpatient CT utilization
- oncology and cardiology diagnostic throughput
- seasonal patterns in elective imaging
For ISOVUE-370, revenue exposure also includes:
- mix of CT protocols that affect dosing per exam
- hospital preference for alternative agents in specific clinical pathways
- volume shifts between contract suppliers
Key Takeaways
- ISOVUE-370’s financial trajectory is driven primarily by procurement contracting, generic substitution, and imaging utilization, not by patent exclusivity.
- Expect structural net price pressure and share erosion risk as contracted equivalents expand.
- Sales patterns are likely lumpy around tender cycles and depend on distributor inventory behavior.
- Competitive differentiation is constrained in an iohexol market where multiple equivalent products are available through GPO and IDN purchasing frameworks.
FAQs
1) What drives quarterly sales volatility for ISOVUE-370?
Tender cycles and distributor inventory timing, plus hospital supply switching during contract renewals.
2) Does ISOVUE-370’s performance track CT volume directly?
It tracks imaging utilization closely, but net sales also move with net pricing and contracted mix.
3) Which factor is more important for long-run ISOVUE-370 revenue: patient demand or contracting?
Contracting and substitution usually dominate long-run share, while patient demand drives baseline utilization.
4) What procurement strategies protect legacy iodinated contrast brands?
Multi-year account relationships, supply continuity, and favorable GPO positioning that preserves net unit pricing.
5) How quickly do hospitals switch from brands to generic iohexol equivalents?
Typically after contract re-tenders or protocol updates, but speed varies by IDN formularies and supply risk tolerance.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. FDA. Drug Approval Reports and labeling database (Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
